Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)
Abstract Background The REVOLENS study compared lung volume reduction coil treatment to usual care in patients with severe emphysema at 1 year, resulting in improved quality-adjusted life-year (QALY) and higher costs. Durability of the coil treatment benefit and its cost-effectiveness at 2 years are...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-018-0796-x |
id |
doaj-7563f304fc84412e921545da32678b8e |
---|---|
record_format |
Article |
spelling |
doaj-7563f304fc84412e921545da32678b8e2020-11-25T01:14:54ZengBMCRespiratory Research1465-993X2018-05-011911910.1186/s12931-018-0796-xCost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)Julie Bulsei0Sylvie Leroy1Jeanne-Marie Perotin2Hervé Mal3Charles-Hugo Marquette4Hervé Dutau5Arnaud Bourdin6Jean-Michel Vergnon7Christophe Pison8Romain Kessler9Vincent Jounieaux10Mathieu Salaün11Armelle Marceau12Sylvain Dukic13Coralie Barbe14Margaux Bonnaire15Gaëtan Deslee16Isabelle Durand-Zaleski17the REVOLENS study groupAP-HP URC Eco IdF, Unité de recherche clinique en économie de la santé d’Ile de FranceService de Pneumologie, CHU de Nice, FHU OncoAge, Université Côte d’AzurService de Pneumologie, INSERM U1250, Hôpital UniversitaireService de Pneumologie, Hôpital Universitaire BichatService de Pneumologie, CHU de Nice, FHU OncoAge, Université Côte d’AzurService d’Oncologie Thoracique, Maladies de la Plèvre, Pneumologie Interventionnelle, Hôpital UniversitaireDépartement de Pneumologie et Addictologie, PhyMedExp, INSERM U1046, CNRS UMR, Hôpital UniversitaireService de Pneumologie, Hôpital UniversitairePôle Thorax et Vaisseaux, Inserm1055, Hôpital Universitaire Grenoble Alpes, Inserm1055, Université Grenoble AlpesService de Pneumologie, Hôpital UniversitaireService de Pneumologie, Hôpital UniversitaireService de Pneumologie, Oncologie Thoracique et Soins Intensifs Respiratoires, Hôpital UniversitaireService de Pneumologie, Hôpital Universitaire BichatDépartement de Pharmacovigilance, Hôpital Universitaire de ReimsUnité d’Aide Méthodologique, Pôle Recherche et Santé Publique, Hôpital Universitaire de ReimsCentre de Recherche et d’Investigation Clinique, Pôle Recherche et Santé Publique, Hôpital Universitaire de ReimsService de Pneumologie, INSERM U1250, Hôpital UniversitaireAP-HP URC Eco IdF, Unité de recherche clinique en économie de la santé d’Ile de FranceAbstract Background The REVOLENS study compared lung volume reduction coil treatment to usual care in patients with severe emphysema at 1 year, resulting in improved quality-adjusted life-year (QALY) and higher costs. Durability of the coil treatment benefit and its cost-effectiveness at 2 years are now assessed. Methods After one year, the REVOLENS trial’s usual care group patients received coil treatment (second-line coil treatment group). Costs and QALYs were assessed in both arms at 2 years and an incremental cost-effectiveness ratio in cost per QALY gained was calculated. The uncertainty of the results was estimated by probabilistic bootstrapping. Results The average cost of coil treatment in both groups was estimated at €24,356. The average total cost at 2 years was €9655 higher in the first-line coil treatment group (p = 0.07) and the difference in QALY between the two groups was 0.127 (p = 0.12) in favor of first-line coil treatment group. The 2-year incremental cost-effectiveness ratio (ICER) was €75,978 / QALY. The scatter plot of the probabilistic bootstrapping had 92% of the replications in the top right-hand quadrant. Conclusion First-line coil treatment was more expensive but also more effective than second-line coil treatment at 2 years, with a 2-year ICER of €75,978 / QALY. Trial registration ClinicalTrials.gov Identifier NCT01822795.http://link.springer.com/article/10.1186/s12931-018-0796-xCoil treatmentSevere emphysemaCost-effectivenessQALY |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Julie Bulsei Sylvie Leroy Jeanne-Marie Perotin Hervé Mal Charles-Hugo Marquette Hervé Dutau Arnaud Bourdin Jean-Michel Vergnon Christophe Pison Romain Kessler Vincent Jounieaux Mathieu Salaün Armelle Marceau Sylvain Dukic Coralie Barbe Margaux Bonnaire Gaëtan Deslee Isabelle Durand-Zaleski the REVOLENS study group |
spellingShingle |
Julie Bulsei Sylvie Leroy Jeanne-Marie Perotin Hervé Mal Charles-Hugo Marquette Hervé Dutau Arnaud Bourdin Jean-Michel Vergnon Christophe Pison Romain Kessler Vincent Jounieaux Mathieu Salaün Armelle Marceau Sylvain Dukic Coralie Barbe Margaux Bonnaire Gaëtan Deslee Isabelle Durand-Zaleski the REVOLENS study group Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study) Respiratory Research Coil treatment Severe emphysema Cost-effectiveness QALY |
author_facet |
Julie Bulsei Sylvie Leroy Jeanne-Marie Perotin Hervé Mal Charles-Hugo Marquette Hervé Dutau Arnaud Bourdin Jean-Michel Vergnon Christophe Pison Romain Kessler Vincent Jounieaux Mathieu Salaün Armelle Marceau Sylvain Dukic Coralie Barbe Margaux Bonnaire Gaëtan Deslee Isabelle Durand-Zaleski the REVOLENS study group |
author_sort |
Julie Bulsei |
title |
Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study) |
title_short |
Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study) |
title_full |
Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study) |
title_fullStr |
Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study) |
title_full_unstemmed |
Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study) |
title_sort |
cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover revolens study (revolens-2 study) |
publisher |
BMC |
series |
Respiratory Research |
issn |
1465-993X |
publishDate |
2018-05-01 |
description |
Abstract Background The REVOLENS study compared lung volume reduction coil treatment to usual care in patients with severe emphysema at 1 year, resulting in improved quality-adjusted life-year (QALY) and higher costs. Durability of the coil treatment benefit and its cost-effectiveness at 2 years are now assessed. Methods After one year, the REVOLENS trial’s usual care group patients received coil treatment (second-line coil treatment group). Costs and QALYs were assessed in both arms at 2 years and an incremental cost-effectiveness ratio in cost per QALY gained was calculated. The uncertainty of the results was estimated by probabilistic bootstrapping. Results The average cost of coil treatment in both groups was estimated at €24,356. The average total cost at 2 years was €9655 higher in the first-line coil treatment group (p = 0.07) and the difference in QALY between the two groups was 0.127 (p = 0.12) in favor of first-line coil treatment group. The 2-year incremental cost-effectiveness ratio (ICER) was €75,978 / QALY. The scatter plot of the probabilistic bootstrapping had 92% of the replications in the top right-hand quadrant. Conclusion First-line coil treatment was more expensive but also more effective than second-line coil treatment at 2 years, with a 2-year ICER of €75,978 / QALY. Trial registration ClinicalTrials.gov Identifier NCT01822795. |
topic |
Coil treatment Severe emphysema Cost-effectiveness QALY |
url |
http://link.springer.com/article/10.1186/s12931-018-0796-x |
work_keys_str_mv |
AT juliebulsei costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT sylvieleroy costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT jeannemarieperotin costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT hervemal costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT charleshugomarquette costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT hervedutau costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT arnaudbourdin costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT jeanmichelvergnon costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT christophepison costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT romainkessler costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT vincentjounieaux costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT mathieusalaun costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT armellemarceau costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT sylvaindukic costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT coraliebarbe costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT margauxbonnaire costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT gaetandeslee costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT isabelledurandzaleski costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study AT therevolensstudygroup costeffectivenessoflungvolumereductioncoiltreatmentinpatientswithsevereemphysemaresultsfromthe2yearfollowupcrossoverrevolensstudyrevolens2study |
_version_ |
1725155762267750400 |